Search

Displaying results 2121 - 2130 of 8517 in total
  1. Drug

    Dextroamphetamine

    go.drugbank.com/drugs/DB01576
    ApprovedIllicitInvestigational

    Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

  2. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  3. Drug

    Anti-inhibitor coagulant complex

    go.drugbank.com/drugs/DB13151
    ApprovedInvestigational

    Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.

  4. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.

  5. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, as JAK inhibition is associated with rapid and sustained anti-inflammatory efects. … [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.

  6. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

  7. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.

  8. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.

  9. Drug

    Dotatate gallium Ga-68

    go.drugbank.com/drugs/DB13925
    ApprovedInvestigationalWithdrawn

    Dotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope. … [A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.

  10. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. … Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol

    Products: ATAZANAVIR (AS SULFATE) CAPSULES 300 MG., ATAZANAVIR ( AS SULFATE ) CAPSULES 150 MG